Tianyu Bio announced that its stock has been limit-up for five consecutive trading days, with the actual price fluctuation significantly impacted by excluding the overall factors of Large Cap and Sector. Over the last five trading days, the stock has accumulated an increase of 60.95% and a Turnover Ratio of 72.68%, which may pose a risk of stock price speculation. Additionally, the company achieved a Net income attributable to the listed company Shareholder of 6.3877 million yuan for the first three quarters of 2024, but the net income after excluding non-recurring items was -1.7207 million yuan, indicating a loss. The company's PB is 5.00 times, far higher than the industry average level of 2.84 times.